Confirmed Faculty | Chair:
Karim Fizazi, MD, PhD
Institut Gustave Roussy
Villejuif, France
Faculty:
John C. Araujo, MD, PhD
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, United States
Oliver Sartor, MD
Tulane University School of Medicine
New Orleans, Louisiana, United States
Eric J. Small, MD
University of California at San Francisco
San Francisco, California, United States
|
 Agenda | 7.00 pm Welcome and introduction
Karim Fizazi, MD, PhD
7.05 pm Clinical opinion poll
7.10 pm Defining the issues and unmet needs in advanced prostate cancer
Karim Fizazi, MD, PhD
7.25 pm Clinical opinion poll
7.30 pm The evolving role of chemotherapy in advanced prostate cancer
Oliver Sartor, MD
7.50 pm Clinical opinion poll
7.55 pm Emerging targeted therapies for castration-resistant prostate cancer
John C. Araujo, MD, PhD
8.15 pm Clinical opinion poll
8.20 pm Concepts in immunotherapy for castration-resistant prostate cancer
Eric J. Small, MD
8.40 pm "The Experts Respond" interactive panel discussion
9.00 pm Concluding remarks and adjournment
Karim Fizazi, MD, PhD
|
Target Audience | Emerging Novel Therapies for Advanced Prostate Cancer: A Practical Approach Toward Clinical Implementation is intended for medical oncologists, radiation oncologists, surgeons, and other healthcare providers interested in the management of prostate cancer.
|
Statement of Educational Need |
Modern treatment approaches in prostate cancer provide
prolonged disease-free survival for many patients with localized disease, but are rarely curative in patients with advanced disease. There is a need to
optimize outcomes and identify new therapies for patients with advanced
prostate cancer. Though recent clinical trials have provided data supporting
new strategies for the management of prostate cancer, integration of new
information and novel regimens into practice is both challenging and necessary.
As new data become available, it is essential that healthcare providers and
researchers are kept abreast of advances in this field.
|
Educational Objectives | At the conclusion of this activity, participants should be able to:
- Identify unmet therapeutic needs in the management of patients with advanced prostate cancer
- Compare traditional chemotherapies with novel chemotherapeutic agents in the management of patients with castration-resistant prostate cancer
- Evaluate novel and emerging targeted therapies for castration-resistant prostate cancer based on recent clinical trial data
- Discuss the rationale and role of immunotherapy for patients with advanced prostate cancer
|
Disclosure of Conflicts of Interest | In accordance with the ACCME Standards for Commercial Support, educational programs sponsored by IUSM must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in an IUSM-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
|
Disclosure of Unlabeled Use | This educational activity may contain discussion of published or and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Indiana University School of Medicine, prIME Oncology, or sanofi-aventis do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Indiana University School of Medicine, prIME Oncology, and sanofi-aventis. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
|
Americans with Disabilities Act | Event staff will be glad to assist you with any special needs (physical, dietary, etc.). Please contact Michael Checkoway prior to the live event at michael.checkoway@oncoservices.com or 678-892-1358.
|
|
|
|
Location | Hilton Chicago
Continental Ballroom
720 South Michigan Avenue
Chicago, Illinois 60605
312-922-4400
|
Date and Time | Saturday, June 5, 2010
6.30 pm – 7.00 pm
Registration and Dinner
7.00 pm – 9.00 pm
Educational Activity
|
Sponsorship | This activity is jointly sponsored by Indiana University School of Medicine (IUSM) and prIME Oncology.
|
Financial Support | Our grateful acknowledgment to the following for an educational grant in support of this activity:
|
Accreditation | Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Indiana University School of Medicine and prIME Oncology. Indiana University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Designation Statement
Indiana University School of Medicine designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
|
Fee Information | There is no fee for this activity and preregistration is not required, however, space is limited.
Dinner will be served.
|
Statement | Not an official event of the American Society of Clinical Oncology (ASCO) Annual Meeting. Not sponsored or endorsed by ASCO or The ASCO Cancer Foundation.
|
|
